Researchers have designed a new and universal PD-L1 cancer diagnostic for tissue samples, enabling more effective use of PD-L1 in assessing cancer growth and severity, and ensuring the prescription of the appropriate therapeutic. This new diagnostic has been shown to be superior in IHC and flow cytometry when compared against other currently used PD-L1 kits.
This diagnostic, when attached with various reporter methods, can be used in a number of detection applications, including in vivo MR, PET, SPECT or CT. As the understanding of the relationship between PD-L1 and cancer evasion of the host immune system continues to grow, there is an increasing demand on imaging and detection of PD-L1 in the body. By providing the most effective method, this technology has use both in the medical field as well as in the lab.
Programmed death-ligand 1 (PD-L1) is a large transmembrane protein that suppresses the immune systems response to foreign substances. PD-L1 works by reducing the proliferation of antigen specific T-cells. Numerous studies are now linking PD-L1 to cancers ability to evade host immune systems. Several PD-L1 therapeutics exist on the market, each associated with its own PD-L1 diagnostic. Published literature show current diagnostics report disconcordant results, presumably due to poor diagnostic design (e.g. epitope choice). The diagnostic generated by inventors at the University of Missouri was designed with this in mind, and has been shown through in vitro testing to be superior to competitor diagnostics.
- Diagnosis PD-L1 levels in patient tissue samples.
- Use in MR, Pet, SPECT, and CT
- PD-L1 detection and monitoring
- Novel diagnostic design